Showing 3181-3190 of 4063 results for "".
- Alcon Collaborates with Eye Care Professionals to Identify and Address Unmet Needs in the Contact Lens Industryhttps://modernod.com/news/alcon-collaborates-with-eye-care-professionals-to-identify-and-address-unmet-needs-in-the-contact-lens-industry/2482485/A new Alcon program aims to identify and address current gaps in contact lens offerings by partnering with eye care professionals. With the new Alcon Innovator Program, 20 ‘innovators’ were selected to receive and offer their patients exclusive access to Alcon’s upcoming product
- Zeiss to Showcase New Digital AI Tools and Surgical Solutions at AAOhttps://modernod.com/news/zeiss-to-showcase-new-digital-ai-tools-and-surgical-solutions-at-aao/2482479/Zeiss will unveil a range of digital enhancements and surgical solutions at the American Academy of Ophthalmology (AAO) conference, running from October 19-21, 2024, in Chicago. These innovations span cataract, corneal refractive, retina, and glaucoma workflows, offering a digitally connecte
- Andreas Pecher to Succeed Dr. Karl Lamprecht as President and CEO of Carl Zeiss AGhttps://modernod.com/news/andreas-pecher-to-succeed-dr-karl-lamprecht-as-president-and-ceo-of-carl-zeiss-ag/2482461/After nearly two decades of leadership at Carl Zeiss AG, Karl Lamprecht, the current President and CEO, has announced that he will not be extending his contract, which is set to expire in the spring of 2025. Andreas Pecher was appointed the company's new President and CEO, effective Apri
- CHMP Upholds Negative Opinion for Apellis' Pegcetacoplan for GA in the EU Following Re-Examinationhttps://modernod.com/news/chmp-upholds-negative-opinion-for-apellis-pegcetacoplan-for-geographic-atrophy-in-the-eu-following-re-examination/2482450/Apellis Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has upheld its previous June 2024 negative opinion on the marketing authorization application for geographic atrophy (GA) treatment pegcetacoplan.
- Atsena Therapeutics Granted FDA Orphan Drug Designation for Gene Therapy Targeting XLRShttps://modernod.com/news/atsena-therapeutics-granted-fda-orphan-drug-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482443/The FDA has granted Orphan Drug Designation to Atsena Therapeutics' product candidate, ATSN-201, which is designed for the treatment of X-linked retinoschisis (XLRS). This gene therapy utilizes the company’s AAV.SPR capsid technology, which enables targeted gene expression in the p
- Aurion Biotech to Present at ESCRS and Ophthalmology Futures European Forumhttps://modernod.com/news/aurion-biotech-to-present-at-escrs-and-ophthalmology-futures-european-forum/2482430/Aurion Biotech announced its upcoming participation in the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), September 6-10, 2024, in Barcelona. The company will showcase clinical data on its allogeneic cell therapy drug candidate, AURN001. Aurion w
- Opthea Announces Executive Leadership Changes and Senior Hireshttps://modernod.com/news/opthea-announces-executive-leadership-changes-and-senior-hires/2482429/Opthea announced several executive leadership changes aimed at bolstering the company’s commercial and clinical expertise as it prepares for the anticipated 2025 topline data readout of phase 3 trials for its lead candidate, sozinibercept, in wet AMD. Daniel Geffken, Co-Founder an
- Alcon Announces New Cataract Surgery Outcomes Data, Hosts Educational Program at ESCRShttps://modernod.com/news/alcon-announces-new-cataract-surgery-outcomes-data-hosts-educational-program-at-escrs/2482426/Alcon is set to unveil new scientific data at the 42nd Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) in Barcelona, from September 6-10, 2024. The company will showcase its surgical ophthalmic products and equipment, highlighting innovations designed to optimize
- Samsara Vision Promotes Jason Herod to Chief Commercial Officerhttps://modernod.com/news/samsara-vision-promotes-jason-herod-to-chief-commercial-officer/2482421/Samsara Vision announced that Jason Herod, formerly Vice President Commercial, International Markets, has been promoted to Chief Commercial Officer (CCO), effective August 15, 2024. Mr. Herod joined Samsara Vision in August 2021, bringing with him over 24 years of extensive experi
- Ocuvex Therapeutics Acquires Visiox Pharmaceuticalshttps://modernod.com/news/visiox-pharmaceuticals-merges-with-ocuvex-therapeutics/2482402/Early-stage ophthalmic biotech company Ocuvex Therapeutics announced an agreement to acquire Visiox Pharmaceuticals. Terms of the deal were not disclosed. Visiox's lead asset is Omlonti (omidenepag isopropyl ophthalmic solution 0.002%), an EP2 rece